First-line immunotherapy in PD-L1-high non-small cell lung cancer: indirect treatment comparison of pembrolizumab and atezolizumab

被引：0
作者：
Griesinger, F. [1 ]
Sibbe, M. S. [2 ]
Hieke-Schulz, S. [2 ]
Buhck, H. [2 ]
Reinmuth, N. [3 ]
Rittmeyer, A. [4 ]
机构：
[1] Pius Hosp Univ Med Oldenburg, Oldenburg, Germany
[2] Roche Pharma AG, Grenzach Wyhlen, Germany
[3] Asklepios Fachkliniken, Munich, Germany
[4] Lungenfachklin Immenhausen, Immenhausen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P448
引用
收藏
页码：227 / 228
页数：2
相关论文
共 50 条
  • [41] Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
    Morimoto, Kenji
    Yamada, Tadaaki
    Kawachi, Hayato
    Tamiya, Motohiro
    Negi, Yoshiki
    Goto, Yasuhiro
    Nakao, Akira
    Shiotsu, Shinsuke
    Tanimura, Keiko
    Takeda, Takayuki
    Okada, Asuka
    Harada, Taishi
    Date, Koji
    Chihara, Yusuke
    Hasegawa, Isao
    Tamiya, Nobuyo
    Nishioka, Naoya
    Katayama, Yuki
    Iwasaku, Masahiro
    Tokuda, Shinsaku
    Kijima, Takashi
    Takayama, Koichi
    [J]. TARGETED ONCOLOGY, 2023, 18 (06) : 915 - 925
  • [42] Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study
    Yan, Xiaoqi
    Wang, Yizong
    Wu, Fei
    Zhou, Guoren
    Shen, Jiannan
    Yu, Shaorong
    [J]. JOURNAL OF THORACIC DISEASE, 2025, 17 (02) : 859 - 871
  • [43] FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC
    Akinboro, Oladimeji
    Larkins, Erin
    Pai-Scherf, Lee H.
    Mathieu, Luckson N.
    Ren, Yi
    Cheng, Joyce
    Fiero, Mallorie H.
    Fu, Wentao
    Bi, Youwei
    Kalavar, Shyam
    Jafri, Samina
    Mishra-Kalyani, Pallavi S.
    Zirkelbach, Jeanne Fourie
    Li, Hongshan
    Zhao, Hong
    He, Kun
    Helms, Whitney S.
    Chuk, Meredith K.
    Wang, Min
    Bulatao, Ilynn
    Herz, Jonathan
    Osborn, Blaire L.
    Xu, Yuan
    Liu, Jiang
    Gong, Yutao
    Sickafuse, Sharon
    Cohen, Rebecca
    Donoghue, Martha
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2221 - 2228
  • [44] A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
    Fu, Jie
    Yan, Yi-Dan
    Wan, Xu
    Sun, Xiao-Fan
    Ma, Xiu-Mei
    Su, Ying-Jie
    [J]. FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [45] Immunotherapy as first-line treatment in metastatic non-small cell lung cancer: A single center experience
    Rauthan, A.
    Patil, P.
    Lahkar, K.
    Murthy, N. Y.
    Vundemodalu, P.
    Ashwath, R.
    Jomi, C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1576 - S1576
  • [46] Correction to: Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Puneet Saxena
    Pawan Kumar Singh
    Prabhat Singh Malik
    Navneet Singh
    [J]. Current Treatment Options in Oncology, 2020, 21
  • [47] Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database
    Grosjean, Heidi A., I
    Dolter, Samantha
    Meyers, Daniel E.
    Ding, Philip Q.
    Stukalin, Igor
    Goutam, Siddhartha
    Kong, Shiying
    Chu, Quincy
    Heng, Daniel Y. C.
    Bebb, D. Gwyn
    Morris, Don G.
    Cheung, Winson Y.
    Pabani, Aliyah
    [J]. CURRENT ONCOLOGY, 2021, 28 (05) : 4213 - 4222
  • [48] Effectiveness and safety of pembrolizumab as first-line treatment for non-small cell lung cancer in real clinical practice
    Romero-Ventosa, Elena Yaiza
    Garcia-Beloso, Nerea
    Lopez-Lopez, Aida
    Martinez-Lopez-de-Castro, Noemi
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [49] Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review
    Guo, Haiyang
    Zhang, Jun
    Qin, Chao
    Yan, Hang
    Luo, Xinyue
    Zhou, Haining
    [J]. MEDICINE, 2024, 103 (03) : E36861
  • [50] First-line immunotherapy in non-small cell lung cancer diagnosed with brain metastases
    Nigen, B.
    Bodergat, T.
    Vaugier, L.
    Pons-Tostivint, E.
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2024, 41 (08) : 571 - 582
12345